TaiMed Biologics (TPEX: 4147) announced that its Board of Directors, at a meeting held last week (April 9), approved a private placement of common shares. The primary objective of this private placement is to introduce strategic investors with strong industry synergies. The Company intends to target leading international pharmaceutical companies with capabilities in new drug licensing. Various collaboration structures are under consideration, including a “licensing-plus-equity participation” model, aimed at strengthening the Company’s capital structure and accelerating the global commercialization of its innovative drug portfolio.

TaiMed Biologics stated that this private placement marks a significant milestone in its global strategic development. The targeted strategic investors are expected to be multinational pharmaceutical companies with strong global market access and R&D capabilities. The collaboration framework will adopt a diversified approach, encompassing not only licensing revenues but also equity participation, thereby establishing long-term and close strategic partnerships. This initiative is expected to enhance the Company’s mid- to long-term working capital while leveraging the expertise of international pharmaceutical partners to strengthen TaiMed’s competitive advantage in the biopharmaceutical sector.

Connecting with Global Capital: CEO Dr. Jimmy Chang to Visit Singapore for Investor Meetings
This important board resolution comes just ahead of CEO Dr. Jimmy Chang’s participation in the “19th QIC CEO Week,” hosted by Quantum International Corp. (QIC), to be held from April 14 to April 15, 2026, at The Fullerton Hotel Singapore. During the event, Dr. Chang will engage in one-on-one meetings with leading global institutional investors to present the Company’s latest operational developments and the strategic significance of the private placement.
TaiMed Biologics emphasized that, through the combination of this newly approved private placement and the upcoming international investor engagement in Singapore, the Company is well-positioned to enter its next phase of growth. Looking ahead, TaiMed will continue to optimize its licensing strategies and bring in strategic partners with a global perspective, aiming to deliver innovative therapies to patients worldwide while maximizing long-term shareholder value.